Leerink analyst Jonathan Chang raised the firm’s price target on Genmab (GMAB) to $34 from $32 and keeps an Outperform rating on the shares. The company’s acquisition of Merus (MRUS) is a long-term positive and helps address a key investor concern, the analyst tells investors in a research note. The firm says the deal brings petosemtamab, a potential “first- and best-in-class” EGFR x LGR5 bispecific antibody to Genmab ‘s existing late-stage pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Video: Merus jumps after deal to be bought, MoonLake sinks after trial data
- Morning Movers: Tilray rises as Trump touts CBD benefits for seniors
- Merus downgraded to Neutral from Buy at Citi
- Genmab to Acquire Merus, Expanding Pipeline and Strategic Growth
- Genmab A/S’s Strategic Acquisition of Merus: A Compelling Buy Despite Short-term EPS Dilution